Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 11:13:866252.
doi: 10.3389/fendo.2022.866252. eCollection 2022.

A systematic review and Meta-analysis of urinary extracellular vesicles proteome in diabetic nephropathy

Affiliations
Meta-Analysis

A systematic review and Meta-analysis of urinary extracellular vesicles proteome in diabetic nephropathy

Xiaonan Ding et al. Front Endocrinol (Lausanne). .

Abstract

Diabetic nephropathy (DN) is a major microvascular complication of both type 1 and type 2 diabetes mellitus and is the most frequent cause of end-stage renal disease with an increasing prevalence. Presently there is no non-invasive method for differential diagnosis, and an efficient target therapy is lacking. Extracellular vesicles (EV), including exosomes, microvesicles, and apoptotic bodies, are present in various body fluids such as blood, cerebrospinal fluid, and urine. Proteins in EV are speculated to be involved in various processes of disease and reflect the original cells' physiological states and pathological conditions. This systematic review is based on urinary extracellular vesicles studies, which enrolled patients with DN and investigated the proteins in urinary EV. We systematically reviewed articles from the PubMed, Embase, Web of Science databases, and China National Knowledge Infrastructure (CNKI) database until January 4, 2022. The article quality was appraised according to the Newcastle-Ottawa Quality Assessment Scale (NOS). The methodology of samples, isolation and purification techniques of urinary EV, and characterization methods are summarized. Molecular functions, biological processes, and pathways were enriched in all retrievable urinary EV proteins. Protein-protein interaction analysis (PPI) revealed pathways of potential biomarkers. A total of 539 articles were retrieved, and 13 eligible records were enrolled in this systematic review and meta-analysis. And two studies performed mass spectrometry to obtain the proteome profile. Two of them enrolled only T1DM patients, two studies enrolled both patients with T1DM and T2DM, and other the nine studies focused on T2DM patients. In total 988 participants were enrolled, and DN was diagnosed according to UACR, UAER, or decreased GFR. Totally 579 urinary EV proteins were detected and 28 of them showed a potential value to be biomarkers. The results of bioinformatics analysis revealed that urinary EV may participate in DN through various pathways such as angiogenesis, biogenesis of EV, renin-angiotensin system, fluid shear stress and atherosclerosis, collagen degradation, and immune system. Besides that, it is necessary to report results compliant with the guideline of ISEV, in orderto assure repeatability and help for further studies. This systematic review concordance with previous studies and the results of meta-analysis may help to value the methodology details when urinary EV proteins were reported, and also help to deepen the understanding of urinary EV proteins in DN.

Keywords: diabetic nephropathy; exosomes; microvesicles; proteome; urinary extracellular vesicles.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Biogenesis of exosomes and microvesicles.
Figure 2
Figure 2
Flow chart of studies selected for systematic review and meta-analysis.
Figure 3
Figure 3
Replicability of urinary EV proteins detected in eligible studies. A1BG, Alpha-1-B Glycoprotein; A2M, Alpha-2-Macroglobulin; ADAM9, a disintegrin and a metalloprotease 9; ALB, Albumin; AMBP, Alpha-1-Microglobulin/Bikunin Precursor; ANPEP, Alanyl Aminopeptidase, Membrane; APOD, Apolipoprotein D; AZGP1, Alpha-2-Glycoprotein 1, Zinc- Binding; CP, ceruloplasmin; DPP4, dipeptidyl peptidase-IV; GC, guanylate cyclase; HBA1, Hemoglobin Subunit Alpha 1; HBB, Hemoglobin Subunit Beta; HP, haptoglobin; HPX, hemopexin; HSPG2, Heparan Sulfate Proteoglycan 2; IGJ, Immunoglobulin J; LRG1, Leucine Rich Alpha-2-Glycoprotein 1; MASP2, mannanbinding lectin serine protease 2; MUC1, mucins; PLG, Plasminogen; PODXL, Podocalyxin; SERPINA3, Serpin Family A Member 3; F, Transferrin; UMOD, Uromodulin.
Figure 4
Figure 4
Proteins of urinary EV with significant difference. A. the proteins in urinary EV significantly upregulated in DN patients compared with healthy control; B1. the proteins in urinary EV significantly upregulated in DN patients compared with healthy control and also showed an increased trend with the progression of DN; B2. the proteins in urinary EV significantly upregulated in DN patients compared with healthy control, whereas showed a decreased trend with the progression of DN; C1. the proteins in urinary EV significantly downregulated in DN patients compared with healthy control, whereas showed an increased trend with the progression of DN; C2. the proteins in urinary EV significantly downregulated in DN patients compared with healthy control and also showed a decreased trend with the progression of DN; D. the proteins in urinary EV significantly downregulated in DN patients compared with healthy control.
Figure 5
Figure 5
GO analysis of all reported proteins. (A) molecular function analysis; (B) cellular components analysis; (C) biological process analysis; (D) pathway analysis.
Figure 6
Figure 6
PPI analysis of potential biomarkers. (A) the PPI analysis of potential biomarkers; (B) KEGG pathways; (C) reactcome pathways.

Similar articles

Cited by

References

    1. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al. . 11. chronic kidney disease and risk management: Standards of medical care in diabetes-2022. Diabetes Care (2022) 45(Supplement_1):S175–s84. doi: 10.2337/dc22-S011 - DOI - PubMed
    1. Doshi SM, Friedman AN. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol (2017) 12(8):1366–73. doi: 10.2215/cjn.11111016 - DOI - PMC - PubMed
    1. Boris D, Vanita RA, George B, Gretchen B, Florence MB, RaShaye F, et al. . 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care (2020) 43(Suppl 1):S14–s31. doi: 10.2337/dc20-S002 - DOI - PubMed
    1. Dong Z, Wang Y, Qiu Q, Zhang X, Zhang L, Wu J, et al. . Clinical predictors differentiating non-diabetic renal diseases from diabetic nephropathy in a large population of type 2 diabetes patients. Diabetes Res Clin Pract (2016) 121:112–8. doi: 10.1016/j.diabres.2016.09.005 - DOI - PubMed
    1. Di Paolo S, Fiorentino M, De Nicola L, Reboldi G, Gesualdo L, Barutta F, et al. . Indications for renal biopsy in patients with diabetes. joint position statement of the italian society of nephrology and the italian diabetes society. Nutr Metab Cardiovasc Dis (2020) 30(12):2123–32. doi: 10.1016/j.numecd.2020.09.013 - DOI - PubMed

Publication types